[ Tips ] 一分鐘使用導覽
商品編號： 9-706-454 出版日期： 2005/12/14 作者姓名： Oberholzer-Gee, Felix;Yao, Dennis 商品類別： Other 商品規格： 7p 再版日期： 2006/08/21 地域： California 產業： Biotechnology;Pharmaceuticals 個案年度： 1980 - 1990
商品敘述：
Amgen Inc.''s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and persons with cancer undergoing chemotherapy, was estimated to be a $1 billion opportunity. After a critical scientific breakthrough, which allowed Amgen to identify the EPO gene, the company applied for a number of patents to protect its achievement. However, much to its surprise, Amgen learned that EPO had already been patented. Genetics Institute, the holder of the patent, demanded a royalty-free cross-license. Amgen''s manager needed to decide how best to compete with its rival.
涵蓋領域：
Intellectual capital;Patents;Business law;Strategic planning;Competition;Strategy formulation;Commercialization
相關資料：
Case Teaching Note, (5-707-542), 8p, by Felix Oberholzer-Gee, Dennis Yao
哪些人也有訂購？